Analysts Lower Q1 EPS Forecast for Pacira BioSciences

On December 11, 2024, Zacks Research reported a reduction in their earnings per share (EPS) forecast for Pacira BioSciences, Inc. (NASDAQ:PCRX) for the first quarter of 2025. The firm now predicts that Pacira will earn $0.60 per share, a slight decrease from their earlier projection of $0.61. The overall consensus for Pacira BioSciences’ full-year earnings for the current fiscal year stands at $2.28 per share. Alongside the Q1 adjustment, Zacks Research has also revised its estimates for future earnings, projecting $0.54 for Q3 2025 and $0.63 for Q2 2026.

Other analysts have also weighed in on Pacira BioSciences with varying price targets and ratings. On November 7, 2024, the Royal Bank of Canada raised their price target from $15.00 to $16.00 while maintaining a “sector perform” rating. Similarly, Jefferies Financial Group adjusted their target from $15.00 to $18.00, giving the stock a “buy” rating as of September 24, 2024. HC Wainwright reaffirmed a “buy” rating with a target price of $39.00 noted on December 4, 2024. Conversely, Barclays cut their price objective significantly from $25.00 to $17.00, while maintaining an “equal weight” rating for the stock. Additionally, Needham & Company reiterated a “buy” rating with an established price target of $22.00 on November 8, 2024. The overall rating for Pacira BioSciences includes two sell ratings, four holds, and five buy recommendations according to MarketBeat, which indicates a consensus rating of “Hold” and a target average price of $23.50.

Current Performance of Pacira BioSciences

On the trading floor, shares of Pacira BioSciences opened at $19.86. The company maintains a debt-to-equity ratio of 0.51, a current ratio of 2.25, and a quick ratio of 1.89. Over the past months, its average price has fluctuated, with a fifty-day moving average of $17.27 and a 200-day moving average of $19.12. The stock has experienced a one-year low of $11.16 and a high of $35.95, giving it a market capitalization of approximately $916.94 million and a price-to-earnings ratio of -9.78, along with a beta of 0.80.

Institutional Holdings in Pacira BioSciences

Recent trading activity shows that several institutional investors and hedge funds have adjusted their positions in Pacira BioSciences. During the second quarter, Innealta Capital LLC established a new holding valued at around $50,000. nVerses Capital LLC increased their stake by an impressive 800%, now owning 1,800 shares valued at $51,000 after acquiring 1,600 additional shares. Similarly, CWM LLC enhanced its position by 713.6%, owning 6,517 shares worth about $98,000 after adding 5,716 shares. Other significant movements included purchases by Virtus Investment Advisers Inc. and Quest Partners LLC, further diversifying ownership. Notably, 99.73% of the stock is held by institutional investors and hedge funds.

About Pacira BioSciences

Pacira BioSciences, Inc. focuses on developing, manufacturing, marketing, and selling non-opioid pain management and regenerative health solutions for healthcare professionals in the United States. Among its product range are EXPAREL, an injectable bupivacaine liposome suspension; ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide; and the iovera system, a non-opioid handheld device that provides cryoanalgesia for targeted pain management.

Pacira, Earnings, Analyst